Your browser is no longer supported. Please, upgrade your browser.
XLRN Acceleron Pharma Inc. monthly Stock Chart
XLRN [NASD]
Acceleron Pharma Inc.
Index- P/E- EPS (ttm)-2.60 Insider Own0.50% Shs Outstand53.36M Perf Week-6.15%
Market Cap5.04B Forward P/E- EPS next Y-2.77 Insider Trans-24.77% Shs Float46.59M Perf Month-3.72%
Income-137.70M PEG- EPS next Q-0.62 Inst Own90.20% Short Float8.25% Perf Quarter-0.43%
Sales75.60M P/S66.62 EPS this Y8.10% Inst Trans- Short Ratio7.62 Perf Half Y88.29%
Book/sh7.76 P/B12.03 EPS next Y8.80% ROA-27.00% Target Price110.27 Perf Year127.56%
Cash/sh7.69 P/C12.15 EPS next 5Y- ROE-30.10% 52W Range37.01 - 108.50 Perf YTD76.14%
Dividend- P/FCF- EPS past 5Y-7.90% ROI-30.30% 52W High-14.87% Beta0.77
Dividend %- Quick Ratio15.10 Sales past 5Y38.30% Gross Margin- 52W Low149.58% ATR5.00
Employees237 Current Ratio15.10 Sales Q/Q53.60% Oper. Margin- RSI (14)41.77 Volatility4.31% 5.06%
OptionableYes Debt/Eq0.00 EPS Q/Q-28.30% Profit Margin- Rel Volume0.58 Prev Close93.39
ShortableYes LT Debt/Eq0.00 EarningsMay 11 AMC Payout- Avg Volume504.33K Price92.37
Recom2.00 SMA20-7.62% SMA50-2.27% SMA20039.09% Volume221,388 Change-1.09%
Apr-06-20Downgrade Goldman Neutral → Sell $73
Feb-27-20Initiated Barclays Overweight $107
Feb-03-20Upgrade Morgan Stanley Equal-Weight → Overweight $122
May-29-19Resumed Goldman Neutral
May-24-19Resumed Citigroup Buy $66
May-03-19Downgrade Barclays Overweight → Equal Weight $54 → $45
Apr-22-19Resumed Oppenheimer Outperform
Feb-28-19Reiterated H.C. Wainwright Buy $72 → $67
Sep-10-18Resumed Morgan Stanley Equal-Weight $55
Jul-13-18Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-10-18Downgrade Piper Jaffray Overweight → Neutral
Jun-29-18Upgrade Goldman Sell → Neutral
Feb-28-18Reiterated Barclays Overweight $50 → $54
Feb-26-18Upgrade JP Morgan Neutral → Overweight
Jan-18-18Resumed Credit Suisse Outperform $55
Nov-07-17Reiterated H.C. Wainwright Buy $57 → $62
Oct-12-17Initiated H.C. Wainwright Buy $57
Sep-15-17Initiated RBC Capital Mkts Sector Perform $44
Jun-13-17Downgrade Oppenheimer Outperform → Perform
May-17-17Initiated Goldman Sell $20
Jun-01-20 02:58PM  
May-29-20 11:06PM  
May-20-20 07:00AM  
May-19-20 07:00AM  
May-13-20 04:01PM  
May-12-20 04:31PM  
10:15AM  
May-11-20 05:45PM  
04:05PM  
May-05-20 07:00AM  
May-04-20 07:00AM  
May-02-20 04:32PM  
Apr-30-20 04:16PM  
Apr-24-20 11:41AM  
Apr-21-20 05:31PM  
Apr-15-20 02:35PM  
Apr-09-20 02:24PM  
Apr-08-20 02:38PM  
07:53AM  
07:05AM  
Apr-07-20 04:05PM  
Apr-06-20 10:03PM  
04:53AM  
Apr-03-20 05:08PM  
Mar-29-20 07:38PM  
12:10PM  
Mar-26-20 06:59AM  
Mar-09-20 04:05PM  
Mar-04-20 08:15AM  
Feb-27-20 05:35PM  
Feb-26-20 08:49AM  
07:00AM  
Feb-20-20 04:10PM  
12:31PM  
Feb-19-20 07:59AM  
Feb-18-20 10:46AM  
07:00AM  
Feb-03-20 10:18AM  
Jan-29-20 09:59AM  
08:30AM  
Jan-28-20 04:22PM  
01:48PM  
10:20AM  
08:13AM  
07:12AM  
05:26AM  
Jan-27-20 06:06PM  
04:22PM  
04:01PM  
12:37PM  
Jan-23-20 04:15PM  
Jan-13-20 06:13PM  
Jan-09-20 06:59AM  
Jan-06-20 07:00AM  
Jan-01-20 02:31PM  
Dec-31-19 11:01AM  
Dec-30-19 07:30AM  
Dec-17-19 10:08AM  
Dec-09-19 04:30PM  
09:22AM  
07:30AM  
Dec-06-19 04:07PM  
12:05PM  
08:00AM  
Dec-04-19 04:01PM  
10:08AM  
Dec-03-19 11:07AM  
07:38AM  
Dec-02-19 07:00AM  
Nov-29-19 09:24AM  
Nov-21-19 03:34PM  
Nov-19-19 10:46AM  
Nov-13-19 03:43PM  
Nov-12-19 05:41AM  
Nov-11-19 09:05AM  
Nov-08-19 04:25PM  
02:24PM  
02:20PM  
12:33PM  
Nov-06-19 09:05AM  
09:05AM  
07:53AM  
Oct-30-19 10:33AM  
Oct-29-19 07:00AM  
Oct-27-19 01:57PM  
Oct-11-19 09:45AM  
Oct-10-19 03:16PM  
Oct-01-19 10:36AM  
Sep-18-19 10:33AM  
10:33AM  
Sep-17-19 04:38PM  
08:40AM  
07:23AM  
Sep-16-19 05:17PM  
04:30PM  
Sep-11-19 10:49AM  
Sep-10-19 06:00PM  
Sep-09-19 11:15AM  
07:00AM  
Sep-04-19 09:03PM  
Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which completed Phase III clinical trials for the treatment of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia. The company is also developing and sotatercept for the treatment of patients with pulmonary hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerApr 09Option Exercise41.2017,226709,71128,442Apr 10 05:29 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerApr 09Sale88.1917,2261,519,16111,216Apr 10 05:29 PM
Veness Adam MSVP, General Counsel and Sec.Apr 08Option Exercise27.976,000167,82027,161Apr 10 05:30 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerApr 08Option Exercise32.7436,7741,204,12947,990Apr 10 05:29 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerApr 08Sale85.5136,7743,144,61411,216Apr 10 05:29 PM
Veness Adam MSVP, General Counsel and Sec.Apr 08Sale85.586,000513,50921,161Apr 10 05:30 PM
Zakrzewski Joseph SDirectorJan 07Option Exercise3.8818,75072,75031,500Jan 09 04:36 PM
Dable Habib JCEO and PresidentJan 03Sale51.243,732191,23067,151Jan 03 09:37 PM
KANGO SUJAYSVP, Chief Commercial OfficerJan 03Sale51.3748024,6579,570Jan 03 09:48 PM
Veness Adam MVP, General Counsel and Sec.Jan 03Sale51.2387544,82614,792Jan 03 09:51 PM
Veness Adam MVP, General Counsel and Sec.Jan 02Sale52.8343422,92815,667Jan 03 09:51 PM
Quisel John DEVP, Chief Business OfficerJan 02Sale52.525,842306,80653,316Jan 03 09:45 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerJan 02Sale52.505,579292,9234,847Jan 03 09:41 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerDec 13Sale50.2811,853595,96910,426Dec 17 06:39 PM
Veness Adam MVP, General Counsel and Sec.Sep 10Sale45.2082437,24116,101Sep 10 08:25 PM
Kumar RavindraSVP & Chief Scientific OfficerSep 10Sale45.243,389153,31886,986Sep 10 08:24 PM
Quisel John DEVP, Chief Business OfficerSep 10Sale45.233,584162,10459,158Sep 10 08:23 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerSep 10Sale45.308,000362,40022,279Sep 10 08:22 PM
Dable Habib JCEO and PresidentSep 10Sale45.235,625254,41270,883Sep 10 08:21 PM
Veness Adam MVP, General Counsel and Sec.Aug 09Sale45.003,268147,06016,925Aug 12 04:18 PM
Veness Adam MVP, General Counsel and Sec.Jul 16Sale40.7153821,90220,193Jul 17 05:49 PM
Quisel John DEVP, Chief Business OfficerJul 09Option Exercise4.828,90842,90862,742Jul 11 04:26 PM
George JeanDirectorJun 28Sale41.1711,812486,3000Jun 28 07:25 PM
George JeanDirectorJun 26Option Exercise26.3537,500988,17541,250Jun 28 07:25 PM
George JeanDirectorJun 26Sale39.1625,6881,005,94215,562Jun 28 07:25 PM
Zakrzewski Joseph SDirectorJun 14Buy38.055,000190,25012,750Jun 17 06:08 PM